Tessa Therapeutics’ head and neck cancer therapy granted Fast Track designation

The US Food and Drug Administration (FDA) granted Fast Track designation to Tessa Therapeutics’ EBV-specific adoptive T Cell therapy for head and neck cancers in September 2015. The designation enables Tessa Therapeutics to have more frequent interactions with the agency, including a potential rolling review of Tessa Therapeutics’ application, and the ability to expedite the development of Tessa Therapeutics’ EBV-specific adoptive T Cell therapy.